All studies involving BTBR T+ Itpr3tf/J


Filter by:
Data set Procedure What's in this data set Panel Sex Age (weeks) Year
Ackert1 body size and weight Body weight, body length, body mass index. Aging study, 6mo, 12mo, 20mo. None BMI, BW inbred   (32) both 26, 52, 87 wks 2008
Ackert1 DXA Body mass, fat mass, lean mass, bone mineral density and content, body area, bone area. Aging study, 6mo, 12mo, 20mo. bone area, body area BMD inbred   (32) both 26, 52, 87 wks 2008
Benoist1 immune cell quantification Regulatory T cells (Treg), thymus, spleen. CD25hi, Foxp3+ None inbred   (33) m 5-6wks 2007
Berndt1 ventilator
with methacholine
Airway resistance. Baseline vs. methacholine-challenged (several doses). None MCh inbred   (37) both 9-12wks 2010
Berndt2 plethysmography
with methacholine
Lung, respiratory function. Baseline vs. methacholine-challenged (several doses). Breathing patterns: efficiency, cycle, airflow, enhanced pause, airway resistance MCh inbred   (29) both 9-12wks 2010
Berndt2 ventilator
with methacholine
Lung, respiratory function. Anesthetized forced oscillation. Baseline vs. methacholine-challenged (several doses). Lung volume, compliance, airflow, airway resistance MCh inbred   (29) both 9-12wks 2010
Berndt4 histopathology Lung adenoma frequency and severity at 20mo. Tumor incidence, cancer, aging. None None inbred   (28) both 87wks 2011
Bolivar3 monitoring system Social interaction (study 1 and study 2). None None inbred   (7) m 8-12wks 2007
Bolivar4 open field test Locomotor activity, exploratory behavior, habituation scores. 15 min test. None None inbred   (14) m 8-12wks 2009
Boon1 body weight
with influenza A (H5N1) virus
Influenza A (H5N1) virus (several doses) vs. baseline. None BW, flu inbred   (23) f 6-9wks 2011
Boon1 health assessment
with influenza A (H5N1) virus
Survival rate, influenza A (H5N1) virus (several doses). Strain H5N1 susceptibility score. None flu inbred   (23) f 6-9wks 2011
Bopp1 health assessment
with Plasmodium berghei
Susceptibility, Plasmodium berghei (malaria). Parasitemia in blood and distribution in brain, spleen, lungs, liver. None None inbred   (31) both 8-12wks 2010
Broad2 genotyping SNP profiling, 131,000+ genomic locations, 1-19,X. None SNPs inbred   (89) 2009
CGD-MDA1 genotyping SNP profiling, 470,000+ genomic locations, 1-19,X,Y,MT. None SNPs inbred   (142) m 2014
CGDpheno1 body size and weight Body weight and length. None BW inbred w/CC8   (72) both 10-13wks 2009
CGDpheno1 complete blood count Hematology. Cell counts, white cells, lymphocytes, neutrophils, monocytes, eosinophils, red cell parameters, hemoglobin, hematocrit, reticulocytes, platelets CBC, RBC, WBC, CHCM, EOS, HCT, HGB, LYM, MCH, MCHC, MONO, MPV, NEUT, PLT, RET, RETIC inbred w/CC8   (72) both 10-13wks 2009
CGDpheno1 DXA Body mass, fat mass, lean mass, bone mineral density. None BMD inbred w/CC8   (72) both 10-13wks 2009
CGDpheno1 lipid profile Cholesterol, HDL, triglycerides, free fatty acids. 4h fast, plasma. None CHOL, FFA, TG inbred w/CC8   (72) both 10-13wks 2009
CGDpheno1 metabolic panel Clinical blood chemistry (plasma). 4h fast. glucose, bilirubin, urea nitrogen, thyroxine, chloride, potassium, sodium, dissolved carbon dioxide BIL, CO2, GLU, T4, TBIL, chem inbred w/CC8   (72) both 10-13wks 2009
Chen1 immune cell quantification Natural killer T cells in peripheral blood, spleen, thymus. invariant. iNK, expressing CD4 None inbred   (38) both 8-10wks 2011
Cowell1 health assessment
with Staphylococcus aureus
Survival rate, Staphylococcus aureus. None None inbred   (13) f 8wks 2012
Cowell1 hormone quantification
with Staphylococcus aureus
Interleukin 6 levels (serum) after infection with Staphylococcus aureus. Kidney and peritoneal fluid. None IL-6, IL6 inbred   (13) f 8wks 2012
Cowell1 in vitro assay
with Staphylococcus aureus
Bacterial load after infection with Staphylococcus aureus. Kidney and peritoneal fluid. In vitro assay. None None inbred   (13) f 8wks 2012
Crabbe1 balance beam
with ethanol
Ethanol i.p. (several doses) vs. control (saline). Missteps count. 3 beam lengths. None EtOH inbred   (8) both 8wks 2003
Crabbe1 body weight
with ethanol
Body weight None BW inbred   (8) both 8wks 2003
Crabbe1 grid test
with ethanol
Ethanol injection (several doses) vs. control (saline). Grid habituation, missteps rate. ataxia EtOH inbred   (8) both 8wks 2003
Crabbe3 body weight
with ethanol
Body weight None BW inbred   (22) both 9-17wks 2003
Crabbe3 rotarod
with ethanol
Baseline and ethanol i.p. 3 fixed speeds (several doses) and accelerating. acquisition, improvement EtOH inbred   (22) both 9-17wks 2003
Crabbe4 alcohol quantification
with ethanol
Blood alcohol concentration after ethanol 2 g/kg i.p., several timepoints. blood alcohol concentration BAC, BEC, EtOH inbred   (21) both 9-17wks 2003
Crabbe4 dowel balance test
with ethanol
Latency to fall 0 min and 30 min post-injection, 2 widths. Ethanol 2 g/kg. None EtOH inbred   (21) both 9-17wks 2003
Crabbe4 grip strength
with ethanol
Baseline vs. 30 min after ethanol 2 g/kg i.p. None EtOH inbred   (21) both 9-17wks 2003
Crabbe4 vertical wire mesh
with ethanol
Latency to fall 30 min post-injection. Ethanol 2 g/kg i.p. None EtOH inbred   (21) both 9-17wks 2003
Crabbe5 parallel rod floor test
with ethanol
Parallel rod balance test, baseline vs. ethanol 2 g/kg i.p.. floor rod EtOH inbred   (8) both 7-14wks 2005
Crowley1 behavior observation
with haloperidol
Observed involuntary repetitive movement. Baseline vs. during and after haloperidol 60d implant (several timepoints). tongue protrusion, overt or subtle chewing movement, jaw tremor None inbred w/CC8   (27) m 9-28wks 2012
Crowley1 body weight
with haloperidol
Baseline vs. after haloperidol 60d implant. None BW inbred w/CC8   (27) m 9-28wks 2012
Crowley1 drug and metabolite quantification
with haloperidol
Haloperidol concentration (plasma). Baseline vs. during and after haloperidol 60d implant (several timepoints). None None inbred w/CC8   (27) m 9-28wks 2012
Crowley1 inclined screen test
with haloperidol
Baseline vs. during and after haloperidol 60d implant (several timepoints). extrapyramidal side effects, EPS None inbred w/CC8   (27) m 9-28wks 2012
Crowley1 open field test
with haloperidol
Locomotor activity, exploratory behavior, involuntary movement. Baseline vs. haloperidol 60d implant (several timepoints). 60 min test. None OFT inbred w/CC8   (27) m 9-28wks 2012
DiPetrillo1 urinalysis Microalbumin, creatinine, ratio. kidney Alb, CREA, MA inbred w/CC7   (34) m 10wks 2012
Donahue1 DXA Body mass, fat mass, lean mass, bone mineral density and content, craniofacial dimensions. whole body without head, spine, skull BMD inbred w/CC7   (30) both 15-16wks 2002
Donahue1 hormone quantification Osteocalcin, insulin-like growth factor 1. None IGF-1, IGF1, INS, OC inbred w/CC7   (30) both 15-16wks 2002
Donahue1 metabolic panel Thyroxine (serum). None T4 inbred w/CC7   (30) both 15-16wks 2002
Donahue18 body weight Pup body weight at day 3. None BW inbred   (15) f 6-8wks 2010
Donahue18 colony observation Reproduction, fecundity. Litter size, percent survival to day 3. None None inbred   (15) f 6-8wks 2010
Donahue18 monitoring system Gestation duration and weight gain during pregnancy. maternal body weight BW inbred   (15) f 6-8wks 2010
Evsikova1 body weight Body weight None BW inbred   (14) both 25wks 2009
Evsikova1 intake monitoring Food intake, water intake at 6mo. Light phase, dark phase, total. None None inbred   (14) both 25wks 2009
Evsikova1 monitoring system Locomotor activity. Aging study. 24h test with 12h light and 12h dark phases. None None inbred   (14) both 25wks 2009
Finn1 bottle choice test Voluntary consumption of ethanol, and ethanol with saccharin (several doses in water). None EtOH inbred   (22) both 8-12wks 2007
Frankel1 electroconvulsion test
with lamotrigine
Electroconvulsive thresholds. Lamotrigine. 2 test sites. clonic, psychomotor, tonic hindlimb extension seizures, frontal and transcorneal stimulation None inbred   (16) both 6-11wks 2000
Gros1 genotype assessment
with Candida albicans
C5 allele sufficiency or deficiency. None None inbred   (36) f 8-12wks 2011
Gros1 in vitro assay
with Candida albicans
Susceptibility to infection with Candida albicans. colony-forming units in kidney, fungal load None inbred   (36) f 8-12wks 2011
Gros2 health assessment
with Plasmodium chabaudi
Survival score and susceptibility, Plasmodium chabaudi. None None inbred   (25) both 8-10wks 2012
Gros2 microscopy
with Plasmodium chabaudi
Percent of Plasmodium chabaudi-infected erythrocytes in blood. None None inbred   (25) both 8-10wks 2012
Hadsell1 body weight Daily body weight gain of cross-fostered pups. None BW inbred   (31) f 14-18wks 2012
Hadsell1 colony observation Maternal nurturing study. Number of pups, survival and weight gain of pups. None inbred   (31) f 14-18wks 2012
Hampton1 ECG Heart rate and wave intervals. Conscious. None ECG, EKG, HR inbred   (17) both 9-12wks 2001
Handel1 body weight Body weight None BW inbred   (14) m 8-10wks 2010
Handel1 organ weights Male reproductive organ weights. Seminal vesicles, testicles. None None inbred   (14) m 8-10wks 2010
Handel1 sperm count Sperm count. Hemocytometer. None None inbred   (14) m 8-10wks 2010
Harrill1 body weight
with isoniazid
Body weight. Isoniazid-treated vs. control. None None inbred   (34) f 8-10wks 2011
Harrill1 histopathology
with isoniazid
Liver pathology scores. Isoniazid-treated vs. control. lymphohistiocytic, hepatocytic None inbred   (34) f 8-10wks 2011
Harrill1 lipid profile
with isoniazid
Cholesterol, triglycerides. Hepatic lipids. Isoniazid-treated vs. control. None CHOL, TG inbred   (34) f 8-10wks 2011
Harrill1 metabolic panel
with isoniazid
Alanine transaminase. Isoniazid-treated vs. control. alanine transaminase ALT inbred   (34) f 8-10wks 2011
Harrill1 organ weights
with isoniazid
Body, liver, kidney weights. Isoniazid-treated vs. control. None None inbred   (34) f 8-10wks 2011
Harrill2 biomarker quantification
with DB289
Kidney injury molecule 1 (KIM-1). DB289-treated vs. control. None KIM-1, KIM1 inbred   (34) f 6-8wks 2012
Harrill2 body weight
with DB289
DB289-treated vs. control. None BW inbred   (34) f 6-8wks 2012
Harrill2 drug and metabolite quantification
with DB289
Kidney metabolite (DB75) concentration. DB289-treated vs. control. None None inbred   (34) f 6-8wks 2012
Harrill2 metabolic panel
with DB289
Blood urea nitrogen, alanine transaminase, creatinine. DB289-treated vs. control. None ALT, BUN, CREA inbred   (34) f 6-8wks 2012
Harrill2 organ weights
with DB289
Kidney and liver weights. DB289-treated vs. control. None LW inbred   (34) f 6-8wks 2012
Harrill2 urinalysis
with DB289
Urine volume, creatinine. DB289-treated vs. control. kidney CREA inbred   (34) f 6-8wks 2012
Haston1 bronchoalveolar lavage assessment
with radiation
Bronchoalveolar cell differential after exposure to radiation (18 Gy). macrophages, lymphocytes, neutrophils, cytospin centrifuge LYM, NEUT inbred   (26) both 15-36wks 2012
Haston1 health assessment
with radiation
Survival rate and health assessment after exposure to radiation. Number of days without respiratory distress (max 26 wks). None None inbred   (26) both 15-36wks 2012
Haston1 histopathology
with radiation
Post exposure to radiation. mast cells, inflammation index None inbred   (26) both 15-36wks 2012
Hawes1 ophthalmoscopy Retinal fundoscopic examination. degeneration, coloboma, hypopigmentation, optic cup, photoreceptor None inbred w/CC7   (41) both 6-7wks 2008
Hawes1 slit lamp Eye morphology. Frequency rates of disorders. retina, cornea, iris, cataract, corneal opacity, lens synechia None inbred w/CC7   (41) both 6-7wks 2008
Hillebrands1 histopathology Kidney pathology at 20mo. perivascular immune cell clusters, aging None inbred   (23) both 87wks 2014
HMDPpheno1 DXA Bone mineral density (whole body, femur, spine). None BMD HMDP   (96) m 16wks 2011
HMDPpheno10 metabolite quantification Liver metabolic profiling. Molecular measures of nucleotides, peptides. 16h fast. None None HMDP   (106) m 16wks 2014
HMDPpheno2 lipid profile Cholesterol, HDL, non-HDL, triglycerides, free fatty acids. 16h fast, plasma. None CHOL, FFA, TG HMDP   (99) m 16wks 2010
HMDPpheno2 NMR Percent fat. None None HMDP   (99) m 16wks 2010
HMDPpheno3 tail cuff Heart rate and blood pressure. Conscious mice. None BP, HR HMDP   (58) m 9-10wks 2012
HMDPpheno4 fear conditioning test Contextual fear, cued fear. None FC HMDP   (94) m 10wks 2011
HMDPpheno5 complete blood count Hematology. cell counts, white cells, lymphocytes, monocytes, granulocytes, red cell parameters, hemoglobin, hematocrit reticulocytes, platelets CBC, RBC, WBC, CHCM, HCT, HGB, LYM, MCH, MCHC, MONO, MPV, PLT, RET, RETIC HMDP   (83) m 16wks 2013
HMDPpheno6 metabolite quantification Liver metabolic profiling. Molecular measures of amino acids. 16h fast. None None HMDP   (106) m 16wks 2014
HMDPpheno7 metabolite quantification Liver metabolic profiling. Molecular measures of carbs, cofactors, vitamins, energy, xenobiotics. 16h fast. None None HMDP   (106) m 16wks 2014
HMDPpheno8 metabolite quantification Liver metabolic profiling. Molecular measures of lipids (non-lysolipids). 16h fast. None None HMDP   (106) m 16wks 2014
HMDPpheno9 metabolite quantification Liver metabolic profiling. Molecular measures of lipids (lysolipids). 16h fast. None None HMDP   (106) m 16wks 2014
Jax4 colony observation Appearance, coat color None None inbred   (61) both 2006
Justice2 complete blood count Hematology. cell counts, white cells, lymphocytes, neutrophils, monocytes, basophils, eosinophils, red cell parameters, hemoglobin, hematocrit, platelets BASO, CBC, RBC, WBC, CHCM, EOS, HCT, HGB, LYM, MCH, MCHC, MONO, MPV, NEUT, PLT inbred   (16) both 12-16wks 2002
Kliethermes1 hole board test Head dipping and other activity measures, hole board with and without objects in two of the holes. 10 min test. None None inbred   (14) both 8wks 2006
Kliethermes1 monitoring system Activity in a novel environment. Distance traveled, number of rears. 30 min test. None None inbred   (14) both 8wks 2006
Kliethermes1 two chamber assay Novel environment preference. Activity in familiar and novel compartments. 20 min test. None None inbred   (14) both 8wks 2006
Kliethermes1 Y-maze Spontaneous alternation. None None inbred   (14) both 8wks 2006
Korstanje1 urinalysis Microalbumin, creatinine, ratio. Aging study, 6mo, 12mo, and 20mo. kidney Alb, CREA, MA inbred   (30) both 52, 78, 104 wks 2008
Korstanje2 histopathology Kidney pathology. Aging study, 6mo, 12mo, 20mo. percent of glomeruli exhibiting mesangial matrix expansion None inbred   (29) m 52, 78, 104 wks 2013
Lightfoot1 body weight Body weight None BW inbred   (41) both 8-9wks 2010
Lightfoot1 running wheel monitoring Distance, duration, speed. None None inbred   (41) both 8-9wks 2010
Marchuk1 histopathology Cerebral infarct volume, stroke susceptibility. Surgical occlusion of distal medial cerebral artery (MCA) to induce ischemia. cerebral infarct volume, stroke susceptibility, surgically-induced ischemia, medial cerebral artery, MCA None inbred   (16) both 11-13wks 2009
Maurer1 body weight
with atenolol, isoproterenol
Isoproterenol or atenolol vs. control. None BW inbred   (23) m 10-12wks 2009
Maurer1 ECG
with atenolol, isoproterenol
Heart rate and wave amplitudes and intervals. Unconscious. Isoproterenol or atenolol vs. control. None ECG, EKG, HR inbred   (23) m 10-12wks 2009
Maurer1 organ weights
with atenolol, isoproterenol
Heart, atria, ventricle weights. Isoproterenol or atenolol vs. control. None None inbred   (23) m 10-12wks 2009
Maurer1 tail cuff
with atenolol, isoproterenol
Heart rate and blood pressure. Conscious mice. Isoproterenol or atenolol vs. control. None BP, HR inbred   (23) m 10-12wks 2009
Metten1 behavior observation
with ethanol
Observed gait, hindlimb splay 10 min and 30 min after ethanol i.p. (several doses). ataxia EtOH inbred   (9) both 8-11wks 2004
Metten1 open field test
with ethanol
Locomotor activity. Ethanol i.p. (several doses) vs. control (saline i.p.). 45s test. None EtOH, OFT inbred   (9) both 8-11wks 2004
Metten2 behavior observation
with ethanol
Ethanol withdrawal severity and handling-induced convulsions. None EtOH, HIC inbred   (15) m 8-11wks 2005
Metten2 body weight
with ethanol
Body weight None BW inbred   (15) m 8-11wks 2005
Mills1 apoptosis assessment Aging study, 6mo, 12mo, 20mo. apoptotic splenocytes None inbred   (30) both 26, 52, 87 wks 2008
Mills1 chromosome instability assessment Chromosome instability. Aging study, 6mo, 12mo, 20mo. reticulocytes with micronuclei, cell damage RET, RETIC inbred   (30) both 26, 52, 87 wks 2008
Moy1 three chamber assay Sociability and preference for social novelty. Autism-relevant behaviors. None None inbred   (17) m 6-7wks 2008
Naggert1 body weight
with high-fat diet
High-fat diet for 8wks. None BW inbred w/CC7   (43) both 5, 21 wks 2003
Naggert1 DXA
with high-fat diet
Body mass, fat mass, lean mass, bone mineral density and content after 8wks on high-fat diet. None BMD inbred w/CC7   (43) both 5, 21 wks 2003
Naggert1 hormone quantification
with high-fat diet
Insulin and leptin after 18wks on high-fat diet. Multiple readings per animal were averaged. None INS, LEP inbred w/CC7   (43) both 5, 21 wks 2003
Naggert1 metabolic panel
with high-fat diet
Glucose (plasma). Baseline vs. high-fat diet (17wks). 4h fast. None GLU inbred w/CC7   (43) both 5, 21 wks 2003
Paigen1 body weight
with high-fat diet
Baseline vs. high-fat diet for 8wks. None BW inbred   (44) both 15-19wks 2000
Paigen1 histopathology
with high-fat diet
Gallstone, gallbladder, and atherosclerosis lesion histopathology after 8wks on high-fat diet. gallstone, mucin, arc, filaments, crystals, cholesterol monohydrate CHOL inbred   (44) both 15-19wks 2000
Paigen1 lipid profile
with high-fat diet
Cholesterol, HDL, non-HDL. 4h fast, plasma. Hepatic lipids. 8wks on high-fat diet. HDL CHOL inbred   (44) both 15-19wks 2000
Paigen1 metabolic panel
with high-fat diet
Alanine transaminase, bile salts (plasma) after 8wks on high-fat diet. 4h fast. alanine transaminase ALT inbred   (44) both 15-19wks 2000
Paigen1 organ dimensions
with high-fat diet
Gallbladder volume after 8wks on high-fat diet. None None inbred   (44) both 15-19wks 2000
Paigen1 organ weights
with high-fat diet
Liver weight after 8wks on high-fat diet. None LW inbred   (44) both 15-19wks 2000
Paigen2 histopathology
with high-fat diet
Aortic lesion size histopathology. Baseline vs. high-fat diet (17wks). None None inbred w/CC7   (43) both 7-9wks, 24-27wks 2002
Paigen2 lipid profile
with high-fat diet
Cholesterol, HDL, non-HDL, triglycerides. Baseline vs. high-fat diet (17wks). 4h fast, plasma. None CHOL, TG inbred w/CC7   (43) both 7-9wks, 24-27wks 2002
Paigen4 lipid profile Cholesterol, HDL, non-HDL, triglycerides. 4h fast, plasma. None CHOL, TG inbred w/CC7   (43) both 10wks 2002
Perlegen2 genotyping SNP profiling, 8,100,000+ genomic locations, 1-19,X,Y,MT. None SNPs inbred   (16) m 2005
Peters1 coagulation test Fibrinogen. prothrombin time, thromboplastin time, fibrinogen. PT, PTT inbred w/CC7   (43) both 10wks 2001
Peters1 complete blood count Hematology. cell counts, white cells, lymphocytes, neutrophils, monocytes, basophils, eosinophils, large unstained cells, red cell parameters, hemoglobin, hematocrit, reticulocytes, platelets, hematology BASO, CBC, RBC, WBC, CHCM, EOS, HCT, HGB, LUC, LYM, MCH, MCHC, MONO, MPV, NEUT, PLT, RET, RETIC inbred w/CC7   (43) both 10wks 2001
Peters4 complete blood count Hematology. Aging study, 6mo, 12mo, 18mo, 24mo. cell counts, white cells, lymphocytes, neutrophils, monocytes, basophils, eosinophils, large unstained cells, red cell parameters, hemoglobin, hematocrit, reticulocytes, platelets BASO, CBC, RBC, WBC, CHCM, EOS, HCT, HGB, LUC, LYM, MCH, MCHC, MONO, MPV, NEUT, PLT, RET, RETIC inbred   (30) both 26, 52, 78, 104 wks 2007
Petkova1 complete blood count Hematology. Aging study, 6mo, 12mo, 18mo, 24mo. white cell count, lymphocytes, neutrophils, eosinophils, monocytes CBC, RBC, WBC, EOS, LYM, MONO, NEUT inbred   (32) both 26, 52, 78, 104 wks 2007
Petkova1 immune cell quantification Aging study, 6mo, 12mo, 18mo, 24mo. B cells. Natural killer cells, total, mature, T cells total, CD4, CD8, naive, central memory, effector cells None inbred   (32) both 26, 52, 78, 104 wks 2007
Pletcher1 body weight Body weight None BW inbred   (32) m 7-9wks 2007
Pletcher1 hormone quantification Corticosterone (serum). None None inbred   (32) m 7-9wks 2007
Pletcher1 open field test Locomotor and anxiety-related behavior. 10 min test. None OFT inbred   (32) m 7-9wks 2007
Pletcher1 tail suspension test Immobility percentage. immobility percentage, hopelessness, depression TST inbred   (32) m 7-9wks 2007
Rhodes1 body weight
with exercise
Exercise wheel group vs. control group. None BW inbred   (12) both 8-15wks 2010
Rhodes1 microscopy
with exercise
Examination of hippocampus dentate gyrus. Exercise wheel group vs. control group. volume, new neurons count, new neurons density None inbred   (12) both 8-15wks 2010
Rhodes1 running wheel monitoring
with exercise
Locomotor activity. Exercise wheel group vs. control group. Distance per day. None None inbred   (12) both 8-15wks 2010
Rusyn2 drug and metabolite quantification
with trichloroethylene
Trichloroethylene metabolites in serum, 2h, 4h, 24h after trichoroethylene exposure. dichloroacetic acid, DCA, trichloroacetic acid, TCA, DCV cyxteine, DCV glutathione DCA, TCA, TCE inbred   (17) m 7wks 2010
Rusyn2 metabolic panel
with trichloroethylene
Blood urea nitrogen, alanine transaminase, aspartate transaminase (serum). Baseline and trichloroethylene-exposed (several timepoints). No fast. None ALT, AST, BUN, TCE inbred   (17) m 7wks 2010
Rusyn5 alcohol quantification
with high-fat diet and ethanol
Alcohol concentration in blood and urine after 4 wk regimen of ethanol vs. control, both groups on high-fat diet. 24h fast. None EtOH inbred   (14) m 8-14wks 2011
Rusyn5 histopathology
with high-fat diet and ethanol
Liver histopathology, injury after 4wk regimen of ethanol vs. control, both groups on high-fat diet. 24h fast. liver steatosis, inflammation, necrosis, total injury scores EtOH inbred   (14) m 8-14wks 2011
Rusyn5 lipid profile
with high-fat diet and ethanol
Hepatic triglycerides after 4wk regimen of ethanol and high-fat diet. 24h fast. None None inbred   (14) m 8-14wks 2011
Rusyn5 metabolic panel
with high-fat diet and ethanol
Alanine transaminase (serum) after 4wk regimen of ethanol vs. control, both groups on high-fat diet. 24h fast. None ALT, EtOH inbred   (14) m 8-14wks 2011
Rusyn5 metabolite quantification
with high-fat diet and ethanol
Homocysteine concentration after 4wk regimen of ethanol vs. control, both groups on high-fat diet. 24h fast. ALT, EtOH, BHMT, DDIT3, HSPA5, SREBF1, protein expression EtOH inbred   (14) m 8-14wks 2011
Rusyn5 organ weights
with high-fat diet and ethanol
Liver weight after 4wk regimen of ethanol vs. control, both groups on high-fat diet. 24h fast. None EtOH, LW inbred   (14) m 8-14wks 2011
Rusyn5 RNA expression profiling
with high-fat diet and ethanol
Liver gene expression after 4wk regimen of ethanol and high-fat diet. 24h fast. mRNA abundance relative to the control (high-fat only) group. None EtOH inbred   (14) m 8-14wks 2011
Rusyn6 drug and metabolite quantification
with trichloroethylene
Trichloroethylene metabolite in blood, liver, kidney after trichloroethylene exposure. dichloroacetic acid, DCA, trichloroacetic acid, TCA, trichloroethanol, TCOH, S-(1-2-dichlorovinyl) glutathione, DCVG, S-(1-2-dichlorovinyl)-L-cysteine, DCVC DCA, EtOH, TCA, TCE inbred   (7) m 6-7wks 2014
Rusyn6 histopathology
with trichloroethylene
Kidney histopathology evaluation after trichloroethylene exposure, relative to controls. BrdU-positive nuclei, kidney injury molecule 1, positive proximal tubules KIM-1, KIM1, TCE inbred   (7) m 6-7wks 2014
Rusyn6 metabolic panel
with trichloroethylene
Blood urea nitrogen (serum). Trichloroethylene-exposed vs. control. None BUN, TCE inbred   (7) m 6-7wks 2014
Rusyn6 organ weights
with trichloroethylene
Liver, kidney weights. Trichloroethylene-exposed vs. control. None TCE inbred   (7) m 6-7wks 2014
Rusyn6 RNA expression profiling
with trichloroethylene
Trichloroethylene effect on mRNA gene expression in liver and kidney, relative to controls. Acox1, Cyp4a10, Ppara. RT-PCR, liver and kidney mRNA gene expression TCE inbred   (7) m 6-7wks 2014
Sanger4 genotyping SNP profiling, 80,000,000+ genomic locations. SNPs and indels. 1-19,X. None SNPs inbred   (37) both 2017
Schwartz2 bronchoalveolar lavage assessment
with ovalbumin
Lung inflammatory changes. Ovalbumin vs. control. alveolar eosinophils, lymphocytes, neutrophils Alb, EOS, LYM, MCh, NEUT inbred   (8) m 6-8wks 2001
Schwartz4 study archive Lung, respiratory response to ozone. Methacholine-sensitized. ozone MCh inbred   (8) both 2004
Seburn1 body weight Body weight None BW inbred   (16) both 7-9wks 2001
Seburn1 intake monitoring Food, caloric, and water intake. Daily. None None inbred   (16) both 7-9wks 2001
Seburn1 monitoring system Locomotor activity and energy metabolism. 24h test. body heat, oxygen volume, carbon dioxide volume, respiratory exchange ratio CO2, O2, RER inbred   (16) both 7-9wks 2001
Seburn2 gait analysis Aging study, 6mo, 18mo. stride length, track width, stride frequency, stance time, swing time, stride time, ratios None inbred   (32) both 26, 52, 78, 104 wks 2008
Seburn2 grip strength Peak tension. 3 trials. Aging study, 6mo, 12mo, 18mo, 24mo. None None inbred   (32) both 26, 52, 78, 104 wks 2008
Shin1 elevated plus maze Exploratory and anxiety-related behaviors. 5 min test. None EPM inbred   (11) m 12-14wks 2016
Shin1 fear conditioning test Pavlovian fear conditioning. None FC inbred   (11) m 12-14wks 2016
Shin1 observational fear learning test Percent time freezing to conditioning and contextual exposure. None None inbred   (11) m 12-14wks 2016
Shin1 open field test Locomotor activity and exploratory behavior. 5 min test. None OFT inbred   (11) m 12-14wks 2016
Shin1 three chamber assay Sociability testing. Tolerance of a novel mouse, a novel object, and second novel mouse vs. first. 10 min test. None None inbred   (11) m 12-14wks 2016
Sugiyama1 tail cuff Heart rate and blood pressure. Conscious mice. None BP, HR inbred   (25) m 10wks 2007
Tarantino1 body weight
with cocaine
Body weight None BW inbred   (45) m 8-11wks 2015
Tarantino1 open field test
with cocaine
Locomotor activity. Baseline (saline) vs. cocaine 20 mg/kg i.p. 30 min test. None OFT inbred   (45) m 8-11wks 2015
Tarantino2 forced swim test
with ovariectomy
Mice with ovariectomy surgery vs. controls (sham surgery), 6 min test. immobility time, hopelessness, depression None inbred   (37) f 8-10wks 2016
Tarantino2 open field test
with ovariectomy
Locomotor activity and exploratory behavior. Mice with ovariectomy surgery vs. controls (sham surgery), 10 min test. None OFT inbred   (37) f 8-10wks 2016
Threadgill1 biomarker quantification
with acetaminophen
Liver cytochrome isoforms. Acetaminophen vs. control. 18h fast. cytochrome isoforms APAP inbred w/CC7   (37) m 8-17wks 2005
Threadgill1 histopathology
with acetaminophen
Liver histopathology, necrosis after acetaminophen vs. control. 18h fast. None APAP inbred w/CC7   (37) m 8-17wks 2005
Threadgill1 metabolic panel
with acetaminophen
Blood urea nitrogen, alanine transaminase, aspartate transaminase (serum), liver enzyme homeostasis. Acetaminophen (several doses) vs. control, several timepoints post-Rx. 18h fast. None ALT, APAP, AST, BUN inbred w/CC7   (37) m 8-17wks 2005
Threadgill1 metabolite quantification
with acetaminophen
Liver protein homeostasis. Acetaminophen vs. control. 18h fast. glutathione, reduced, oxidized, total, ratio APAP inbred w/CC7   (37) m 8-17wks 2005
Threadgill1 organ weights
with acetaminophen
Liver weight after acetaminophen (several doses) vs. control. 18h fast. glutathione, reduced, oxidized, total, ratio APAP, LW inbred w/CC7   (37) m 8-17wks 2005
Tomasini1 biomarker quantification Fibronectin. None None inbred   (25) both 9wks 2007
Tordoff3 body weight Body weight None BW inbred w/CC7   (40) both 9-15wks 2002
Tordoff3 bottle choice test Various salt solutions (several concentrations) vs. water. sodium chloride, calcium chloride, calcium lactate, sodium lactate, taste preference CaCl2, CaLa, NaCl, NaLa inbred w/CC7   (40) both 9-15wks 2002
Tordoff3 DXA Body mass, fat mass, lean mass, bone mineral density and content. None BMD inbred w/CC7   (40) both 9-15wks 2002
Tordoff3 metabolic panel Ionized and total blood calcium, blood pH. None None inbred w/CC7   (40) both 9-15wks 2002
Tordoff3 monitoring system Bleeding time to collect approx 30 µL. None None inbred w/CC7   (40) both 9-15wks 2002
UCLA1 genotyping SNP profiling, 132,000+ genomic locations, 1-19,X None SNPs HMDP   (248) both 2018
Vinyard1 body weight Body weight None BW inbred   (21) both 6-8wks 2009
Vinyard1 bone dimensions Craniofacial bone dimensions. maximum gape, jaw-opening, condyle None inbred   (21) both 6-8wks 2009
Wahlsten1 elevated plus maze Locomotor, exploratory, and anxiety-related behavior. None EPM inbred   (21) both 9, 12 wks 2003
Wahlsten1 histopathology Corpus callosum, hippocampus, anterior commisure. corpus callosum, hippocampus, anterior commissure None inbred   (21) both 9, 12 wks 2003
Wahlsten1 open field test Locomotor, exploratory, and anxiety-related behavior. 5 min test. None OFT inbred   (21) both 9, 12 wks 2003
Wahlsten1 organ weights Brain weight. None None inbred   (21) both 9, 12 wks 2003
Wahlsten2 behavior observation Wildness scoring during various phenotyping tests. bites, escapes, vocalization, wildness, capture and hold None inbred   (21) both 10-12wks 2003
Willott1 acoustic startle test Acoustic startle response, prepulse inhibition. None ASR, PPI inbred w/CC7   (40) both 5-6wks 2002
Willott1 body weight Body weight None BW inbred w/CC7   (40) both 5-6wks 2002
Wiltshire1 elevated plus maze Locomotor activity. None EPM inbred   (38) both 12-14wks 2010
Wiltshire1 light-dark box Light-dark test. Anxiety-related behavior. None None inbred   (38) both 12-14wks 2010
Wiltshire1 open field test Locomotor activity. None OFT inbred   (38) both 12-14wks 2010
Wiltshire2 drug and metabolite quantification
with fluoxetine
Fluoxetine and norfluoxetine concentration (serum) after fluoxetine. None None inbred   (30) m 9-11wks 2011
Wiltshire2 open field test
with fluoxetine
Locomotor activity, exploratory and anxiety-related behavior. Fluoxetine-treated vs. control. 7 min test. None OFT inbred   (30) m 9-11wks 2011
Wiltshire2 tail suspension test
with fluoxetine
Immobility. Fluoxetine-treated vs. control. 5 min test. immobility time, hopelessness, depression TST inbred   (30) m 9-11wks 2011
Wiltshire3 biomarker quantification
with fluoxetine
Brain tissue survey of 30 biochemical analytes. Fluoxetine-treated vs. control. 21d. cerebral cortex None inbred   (30) m 10-11wks 2011
Wiltshire4 immune cell quantification
with cancer drugs
In vitro study of 4 cancer chemotherapies (BEZ235, doxorubicin, idarubicin, selumetinib) vs. control. Effect on immune cells. Normalized data. B cells, T cells, monocytes, IC50 MONO inbred w/CC7   (36) m 10wks 2015
Xing1 ECG Heart rate and wave intervals. Conscious. Aging study, 6mo, 12mo, 20mo. None ECG, EKG, HR inbred   (29) both 26, 52, 87 wks 2008
Xing2 gait analysis Aging study, 6mo, 12mo, 18mo. None None inbred   (31) both 26, 52, 78 wks 2010
Yuan1 body weight Aging study, 6mo, 12mo, and 18mo. None BW inbred   (33) both 26, 52, 78 wks 2007
Yuan1 hormone quantification Insulin-like growth factor 1 (serum). Aging study, 6mo, 12mo, and 18mo. None IGF-1, IGF1, INS inbred   (33) both 26, 52, 78 wks 2007
Yuan2 colony observation Life span study. Survival curves. Aging study. None None inbred   (31) both max lifespan 2007
Yuan3 lipid profile Cholesterol (HDL). Aging study, 6mo, 12mo, 18mo. 4h fast, plasma. None CHOL inbred   (32) both 26, 52, 78 wks 2008
Yuan3 metabolic panel Clinical blood chemistry. Aging study, 6mo, 12mo, 18mo. albumin, thyroxine, total protein, bilirubin, urea nitrogen, disolved carbon dioxide. Iron, calcium, chloride, magnesium, phosphorus, potassium, sodium. Alkaline phosphatase, alanine transaminase, lipase ALP, ALT, Alb, BIL, CO2, LIP, T4, TBIL, TP, chem inbred   (32) both 26, 52, 78 wks 2008
Yuan4 colony observation Observed age at vaginal opening (patency). Aging study. None None inbred   (33) f 2-9wks 2009